Pubmed search on Ceramides
Tim Peterson touched upon the role of sphingolipids in aging in his senolytic talk at the Longevity Summit: Senolytics Topically Administered to Skin for Antiaging Effects - #30 by RapAdmin
The chatbots seem to think Omega 3 fatty acids reduce ceramide in the body. As is often the case with chatbots, I am not actually able to locate the articles referenced. Perhaps someone with more skills or access to more databases can find these references.
"Are there any known drugs or supplements that inhibit or reduce sphingolipids or ceramides in the body? Provide citations.
Yes, there are several known drugs and supplements that can inhibit or reduce sphingolipids or ceramides in the body. According to a study conducted by the National Center for Biotechnology Information, statins, plant sterols, and omega-3 fatty acids are all known to reduce levels of sphingolipids in the body. Additionally, the study found that omega-3 fatty acids and plant sterols can also reduce levels of ceramides in the body.
References:
- Arino, J., & Planells, R. (2016). Lipid-lowering drugs and dietary supplements with lipid-lowering effects. Trends in Pharmacological Sciences, 37(1), 37-49. doi:10.1016/j.tips.2015.11.001
The results showed that omega-3 fatty acid supplementation significantly decreased the levels of certain ceramide subspecies with small interfacial headgroups compared to the placebo group. These ceramide subspecies are thought to be particularly harmful to cardiovascular health. In addition, the omega-3 supplementation also improved endothelial function, which is an important marker of cardiovascular health.
Title: Omega-3 Fatty Acid Supplementation Decreases Plasma Ceramide Subspecies with Small Interfacial Headgroups and Attenuates Endothelial Dysfunction in Adults with Moderate Hypertriglyceridemia
Authors: West AL, Burdge GC, Calder PC.
Journal: Journal of Nutrition. 2016 May;146(5): 992-8.
Yes - that is what I’ve found too - really bizarre. The AI chatbots seem to make stuff up. I ask for the specific paper, they give me a journal/title and date, and there is not such thing. Don’t waste too much time on the chatbots - not too helpful except as a technology demo right now (at least in the science area).
Finally, a biomarker is only useful in the clinic when it is able to guide effective interventions. Randomized clinical trials based on ceramide measures have not been reported. However, several reports have found that ceramide concentrations are significantly decreased by caloric restriction, gastric bypass, aerobic exercise and statin therapy. A significant decrease in plasma ceramides was observed among subjects taking simvastatin (alone or in combination with ezetimibe) and rosuvastatin. Despite the paucity of outcome studies, these data are promising in that therapies already known to be effective at reducing risk of heart disease are also able to modify plasma ceramide concentrations.
More research on Sphingolipids:
Age-related muscle dysfunction and sarcopenia are major causes of physical incapacitation in older adults and currently lack viable treatment strategies. Here we find that sphingolipids accumulate in mouse skeletal muscle upon aging and that both genetic and pharmacological inhibition of sphingolipid synthesis prevent age-related decline in muscle mass while enhancing strength and exercise capacity. Inhibition of sphingolipid synthesis confers increased myogenic potential and promotes protein synthesis. Within the sphingolipid pathway, we show that accumulation of dihydroceramides is the culprit disturbing myofibrillar homeostasis. The relevance of sphingolipid pathways in human aging is demonstrated in two cohorts, the UK Biobank and Helsinki Birth Cohort Study in which gene expression-reducing variants of SPTLC1 and DEGS1 are associated with improved and reduced fitness of older individuals, respectively. These findings identify sphingolipid synthesis inhibition as an attractive therapeutic strategy for age-related sarcopenia and co-occurring pathologies.